Avner Lushi - 20 Feb 2026 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Reporting relationship: Director
Issuer ticker: SLXN
Reported as of: 20 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2026, 16:06:04 UTC
Prior SEC filing: 31 Dec 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Mirit Horenshtein Hadar, Attorney-in-fact

Key filing fact

Avner Lushi filed Form 4 for Silexion Therapeutics Corp (SLXN) on 23 Feb 2026.

Key facts

This page summarizes Avner Lushi's Form 4 filing for Silexion Therapeutics Corp (SLXN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Feb 2026, 16:06.

Change

Previous filing in this sequence was filed on 31 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002033604 Primary reporting owner

Lushi Avner

Relationship: Director
Address: 5 NARCISSUS BOULEVARD, RAMAT GAN, ISRAEL
Signature: /s/ Mirit Horenshtein Hadar, Attorney-in-fact
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLXN transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +9,091
Change %: +56%
Price: $0.000000
Shares after: 25,399
Date: 20 Feb 2026
Ownership: By Guangzhou Sino-Israel Biotech Fund
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLXN transaction Derivative

Stock Option (right to buy ordinary shares)

Award

Transaction value: $0
Shares: +10,685
Change %
Price: $0.000000
Shares after: 10,685
Date: 20 Feb 2026
Ownership: By Guangzhou Sino-Israel Biotech Fund
Underlying class: Ordinary Shares
Underlying amount: 10,685
Exercise price: $1.65
Footnotes: F2, F3, F4

SLXN holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,872
Date: 20 Feb 2026
Ownership: By Guangzhou Sino-Israel Biotech Fund
Underlying class: Ordinary Shares
Underlying amount: 1,872
Exercise price: $18.90
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares|), in respect of director services provided by the Reporting Person to the Issuer. The grant was approved by the Issuer's board of directors.

Footnote F2

The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.

Footnote F3

The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by the Reporting Person to the Issuer, which grant was approved by the Issuer's board of directors.

Footnote F4

The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

Footnote F5

There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.